Olaparib is approved for several therapeutic indications. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether olaparib, in combination with abiraterone and prednisone or prednisolone, provides added benefit over the appropriate comparator therapy (ACT) in adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not indicated. In comparison with the ACT, the Institute found a hint of minor added benefit in treatment-naive patients under 65 years of age, and a hint of lesser benefit in treatment-naive older patients.

https://www.miragenews.com/olaparib-boosts-benefit-for-some-metastatic-1047352/

#miragenews